Extended cv fredrik nicklasson
!In November 2013 I started up Scius Pharma Support AB, an independent consulting firm aimed to
support product development initiatives of life science companies of all sizes.
!Before that, I have worked as line manager, project manager and specialist in the CMC area of the
pharma industry for over 13 years. My main expertise lies within the area of formulation development
and dosage form design, stretching from proof of concept work through to tech transfer for
!I have set up and executed several projects with contractors in the fields of material characterisation,
product development and manufacturing of drug products. This work has involved establishing
contracts and agreements as well as monitoring work progress and compliance with quality standards,
!Working cross-functionally within an international pharmaceutical company has given me experience
in broad science-based decision making, as well as experience in working with international teams
together with professionals from Europe, Asia and the Americas, both inside the company as well as
!Other types of assignments I have some experience from includes technical due diligence of potential
acquisition targets and IP protection work. I am co-inventor of several patents and have also served as
technical expert in patent litigation cases.
!My experience from working in the fast-paced OTC segment has allowed me to be part of several
successful product launches. It also has provided me with ample opportunity to work closely with the
marketing organisation within the companies, thus gaining valuable insights in the business aspects of
!My professional background, together with my scientific background as a pharmacist with a PhD in
pharmaceutics, gives me a broad understanding of drug development and commercialisation.
!McNeil AB (A Johnson & Johnson subsidiary)
!!!Roles and responsibilities:
!Manager Formulation Development (2009 – 2013)
Team manager (line manager) leading a product development team of 6-8 colleagues working with
formulation development and GMP-manufacturing for clinical studies in phase I and phase III as well
as 1/10 scale regulatory stability batches. The team included both junior and senior personnel. The role
Regulatory quality of the deliverables of the team.
Planning and follow-up of the tasks of the team.
Resource allocation to secure the project deliveries.
Performance planning and review (goals and objectives, annual salary and bonus review).
Coaching of individuals and teams to increase team effectiveness.
Scientific and professional development of individuals in team.
Occupational safety, health and environment compliance of the team.
!!New Product Development Project CMC Coordinator (2006 – 2013)
Coordinator of R&D activities in support of NPD (New Product Development) projects. Lead cross-
functional R&D teams (CMC Regulatory, clinical, formulation and analytical development). The role
Planning overall R&D activities for the project, including cost and resource requirements.
Execution of R&D deliverables according to project timeline.
Operational decision-making on pivotal and supporting studies.
Reporting progress to project governance and stakeholders.
!!Specialist Formulation Development (2000 – 2009)
Formulation specialist with progressively more senior responsibilities (organisational titles: Research
Scientist, Senior Research Scientist, Research Associate, Senior Research Associate). The role
included a wide variety of work assignments, from hands-on to purely intellectual, giving experience
Planning and executing batch manufacture in laboratory scale and up to 1/10 scale.
Developing formulations from prototype to tech transfer (solid, semisolid and liquid dosage
Performing activities under GMP (manufacturing, training, qualification, validation,
Developing CMC documentation for regulatory files.
Scientific evaluations of external technologies.
IP and patents (patent writing, freedom to operate evaluations, competitor activities
!PhD Pharmaceutics, 2000
!MSc Pharmacy, 1994
!Swedish Academy of Pharmaceutical Sciences (including role as secretary of the Section for
Pharmaceutics & Biopharmaceutics 2007-2009)
Multivariate methods in the development of a new tablet formulation: Optimization and validation., Drug Dev. Ind. Pharm. 30, 1037-1049. Authors: Gabrielsson, Lindberg, Pålsson, Nicklasson, Sjöström, Lundstedt.
Multivariate methods in the development of a new tablet formulation., Drug Dev. Ind. Pharm. 29, 1053-1075. Authors: Gabrielsson, Lindberg, Pålsson, Nicklasson, Sjöström, Lundstedt.
Compression shear strength and tableting behavior of microcrystalline cellulose agglomerates modulated by a solution binder (polyethylene glycol). Pharm Res 18, 873-877. Authors: Nicklasson, Alderborn.
Compression mechanics of pharmaceutical aggregates – studies on the tabletting of spheronised aggregates with varying composition and porosity, Ph. D. Thesis, Uppsala university. Authors: Nicklasson.
Analysis of the compression mechanics of pharmaceutical agglomerates of different porosity and composition using the Adams and Kawakita equations. Pharm. Res. 17, 949-954. Authors: Nicklasson, Alderborn.
Modulation of the tabletting behaviour of microcrystalline cellulose pellets by the incorporation of polyethylene glycol. , Eur. J. Pharm. Sci. 9, 57-65. Authors: Nicklasson, Alderborn.
Tabletting behaviour of pellets of a series of porosities – a comparison between pellets of two different compositions. , Eur. J. Pharm. Sci. 8, 11-17. Authors: Nicklasson, Johansson, Alderborn.
Occurrence of fragmentation during compression of pellets prepared from a 4 to 1 mixture of dicalcium phosphate and microcrystalline cellulose. Eur. J. Pharm. Sci. 7, 221-229. Authors: Nicklasson, Johansson, Alderborn.
Effect of pellet size on degree of deformaion and densification during compression and on compactability of microcrystalline cellulose pellets, Int. J. Pharm. 163, 35-48. Authors: Johansson, Nicklasson, Alderborn.
Process For The Manufacture Of Nicotine-Comprising Chewing Gum And Nicotine-Comprising Chewing Gum Manufactured According To Said Process McNeil PPC Inc Inventor(S): Hugerth, Lindell, Nicklasson, Hendenstrom, Koll, Sowden, Luber, Kriksunov, Bunick, Chen, Olsson, Szymczak. Application No. WO2010US49974A, Filed:20100923 , Published: 20110331
Multi Portion Intra-Oral Dosage Form And Use Thereof McNeil AB Inventor(S): Lindell,; Thyresson, Nicklasson, Bunick, Luber, Hugerth. Application No. WO2009SE51163A, Filed:20091013 , Published: 20100422
A Liquid Formulation For Administering Nicotine Mcneil AB Inventor(S): Hedenström, Nicklasson. Application No. WO2008SE279A, Filed:20080421 , Published: 20081120
Coated Oral Nicotine Formulation Buffered With Amino Acid McNeil AB Inventor(S): Andersson, Bergengren, Bosson, Hugerth, Nicklasson, Olsson. Application No. WO2008SE278A, Filed:20080421 , Published: 20081120
Oral Nicotine Formulation Buffered With Amino Acid McNeil AB Inventor(S): Andersson, Bergengren, Bosson, Hugerth, Nicklasson, Olsson. Application No. WO2008SE277A, Filed:20080421 , Published: 20081120
Pharmaceutical Product For Intraoral Delivery Of Nicotine Comprising Trometamol As Buffering Agent McNeil AB Inventor(S): Steen, Dymitrowics, Hugerth, Waltermo, Pålsson, Olsson, Nicklasson, Schlüter, Thyresson, Mody, Bosson, Lindell. Application No. WO2007SE364A, Filed:20070418 , Published: 20071122
Means For Transdermal Administration Of Nicotine Pfizer Health AB Inventor(S): Lindell, Nicklasson, Thyresson. Application No. WO2005IB673A, Filed:20050310 , Published: 20060511
Formulations Comprising An Active Ingredient And Cocoa Powder And Use Thereof Pharmacia AB Inventor(S): Lindberg, Lindell, Martino, Nicklasson, Thyresson. Application No. WO2004IB860A, Filed:20040316 , Published: 20041007
Formulations Comprising Tolterodine And Cocoa Powder And Use Thereof Pharmacia AB Inventor(S): Lindberg, Lindell, Katarina, Martino, Nicklasson, Thyresson. Application No. WO2004IB859A, Filed:20040316 , Published: 20041007
Seasonal Influenza Immunization Questionnaire Live, Attenuated (Nasal Administration) FLUMIST Available for healthy patients, 2 years through 49 years of age For patients: The following questions will help us determine if you are eligible to receive influenza vaccine today. Please answer these questions by checking the boxes. If the question is not clear, please ask us to explain it. Patient
Family Name____________________ Date Form Completed____________ CPLC PERMISSION SLIP/EMERGENCY RELEASE FORM Youth’s Name:___________________________________ Grade______________ DOB__________ Male/Female_______ Address___________________________City__________St/Zip__________ School_________________Parent (s)/Guardian Name_____________________________________ Home Phone____________